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ABSTRACT
Background: self-expanding metal stents are currently being
used as a definitive palliative treatment for malignant colorectal
obstruction in patients with incurable disease. Few studies have fol-
lowed large numbers of patients from stent placement until death,
and those few have reported conflicting results in the long-term clin-
ical outcome data.
Aims: this study evaluated the clinical effectiveness of stent place-
ment for malignant colorectal obstruction throughout the patients’
lives and related factors affecting stent patency, clinical success and
complications.
Methods: this was a multicentre, retrospective study of 89 con-
secutive patients who had undergone attempted expandable stent
placement for symptomatic malignant colorectal obstruction during
a 10-year period. Data were collected to analyse the sustained relief
of obstructive symptoms throughout the patients’ lives, as well as
the technical success, immediate clinical success, stent patency,
complications, reinterventions, survival, prognostic factors associated
with stent patency and long-term clinical efficacy and risk factors
for complications.
Results: technical and immediate clinical success were achieved
in 95.5% and 91.0% of patients, respectively. A total of 68 out of
89 patients (76.4%) maintained relief of obstruction from stent
implantation until death without reintervention. Twenty patients
(22.5%) had complications including perforation (n = 4; 4.5%), stent
obstruction (n = 8; 9.0%), migration (n = 5; 5.6%) and haemorrhage
(n = 3; 3.4%). Stent-related mortality was seen in 1 patient (1.1%).
The estimated median survival and estimated mean stent patency
were 87.0 and 322.7 days, respectively. In total, 12 of the initial
89 patients (13.5%) needed a colostomy for long-term relief of the
obstructive symptoms. Univariate and multivariate analysis detected
no significant prognostic factors associated with stent patency, long-
term clinical efficacy and risk factors for complications; however,
the multivariate logistic model revealed a non-significant trend by
which the use of chemotherapy was a risk factor for migration
(OR = 11.89; p = 0.06).
Conclusions: for palliation of incurable malignant colorectal
obstruction, expandable stents can provide sustained relief of obstruc-
tion in approximately 75% of patients. The procedure is associated
with acceptable morbidity, need for reintervention and minimal mor-
tality.
Key words: Self-expanding metal stent. Colorectal obstruction.
Endoscopic definitive palliation.
INTRODUCTION
Colorectal cancer is one of the most common malig-
nancies worldwide (1). In patients with colorectal cancer,
obstruction occurs in 15 to 20% (2). Most of these patients
have advanced disease and are often elderly, with signif-
icant comorbidities (2-4). In this group of patients, curative
resection is not frequently feasible (4,5). Therefore, pal-
liation is the primary aim in these patients (3,6,7). Emer-
gency surgical decompression is associated with high mor-
tality and morbidity figures (8,9). In addition, surgery
often involves creation of a colostomy, reversal of which
would not be possible in up to 50% of patients. This inter-
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vention would thus have a profound negative impact on
quality of life (7-9). 
First reported by Dohmoto et al. (10), self-expandable
metal stents (SEMS) have been increasingly used as a min-
imally invasive, nonsurgical treatment for either palliation
or pre-operative bridging to 1-stage surgery procedure in
malignant colorectal obstruction (1-10). A pooled analysis
of 1,198 patients demonstrated an immediate clinical suc-
cess rate of 92.7% in the palliative group (11); however,
complications were recorded including perforations (3.8%),
migration (11.8%), re-obstruction (7.3%) and stent-related
mortality (0.58%). A systematic review comparing endo-
scopic palliation with surgery suggested that stenting was
associated with more positive outcomes when compared
with surgery, including overall shorter hospital stays, and
a lower rate of serious adverse events (9). 
Although the initial decompression rate using SEMS in
acute colorectal obstruction is high, there are concerns about
the long-term clinical efficacy and late complications of
the stents in the palliative setting. Few studies followed the
majority of patients until death after stent placement, and
there is a small amount of long-term clinical outcomes data
with conflicting results. Recent studies reported that a single
palliative SEMS implantation is associated with long-term
(until death) success rates up to 80%, although the compli-
cation rate is nearly 25% (6,7,12,13). These results, how-
ever, conflict with other studies reporting short- and long-
term clinical failure in more than 50% of patients, along
with a high number of severe complications (4,5). Further-
more, several risk factors have been associated with stent
patency, complications and clinical outcomes, as well as
with conflicting results (1,6,12-14). The question remains:
are SEMS used for definitive palliation of malignant col-
orectal obstruction as successful as those used as a bridge
to surgery? 
The aim of this study was to evaluate the sustained relief
of obstructing symptoms from stent placement until death
in all patients, including the incidence of complications and
the need for reinterventions, risk factors for complications
and prognostic factors associated with stent patency and
long-term clinical efficacy after SEMS placement in the
palliative treatment of patients with malignant colorectal
obstruction.
METHODS
Patients and setting
Interventional endoscopy database records from 4 insti-
tutions were retrospectively reviewed to identify all patients
who had undergone consecutive attempted SEMS place-
ment for symptomatic malignant colorectal obstruction
between October 2001 and August 2011. The following cri-
teria were used for inclusion in this study: 1-palliative intent
to treat in patients with obstructive symptoms, 2-histolog-
ically confirmed malignancy, 3-inoperable disease based
on advanced tumour stage, metastatic disease or medical
comorbidity and 4-complete follow-up until patient death
at the time of data collection. The exclusion criteria were
as follows: a) evidence of bowel perforation or other
obstructions in the gastro-intestinal tract; b) previous pal-
liative stent placement for the same condition; and c)
patients with tumoral strictures and no obstructive symp-
toms. 
Colorectal obstruction was diagnosed by clinical findings
and confirmed using a colonoscopy or computed tomog-
raphy. The data were collected from a variety of sources,
including patients’ charts (manual and electronic), clinical
notes, radiology and endoscopic reports, our prospective
database, follow-up clinic visits and telephone interviews
with treating physicians or family during follow-up or at
the time of manuscript preparation. Several investigators
participate in this task to obtain the following data: patient
demographics, technical success, clinical success, stent
model, stent diameter, type of malignancy (intrinsic or
extrinsic), location of obstruction, complications, reinter-
ventions, palliative chemotherapy, need for surgery and
survival. Patients with incomplete data were excluded from
the study. This study was conducted at 4 institutions (3 ter-
tiary referral academic centres and 1 general district hos-
pital). All patients provided informed written consent prior
to their procedures. Each ethics committee involved
approved this retrospective study.
Technique and stents
The technique used for stent placement has been
described elsewhere (2,15). Briefly, all procedures were
performed with patients in the left lateral position under
sedation with propofol administered by an anaesthesiol-
ogist. In some cases, patients were shifted to the supine
position during the procedure and stent deployment for a
better anatomic view under fluoroscopy. No oral bowel
preparation was given, and patients underwent bowel
cleansing by using repeated enemas. The stricture was
assessed with a triple-lumen biliary catheter and a biliary
guidewire under endoscopic and fluoroscopic guidance.
The length of the stricture was assessed either endoscop-
ically or fluoroscopically by injection of water-soluble
contrast. Balloon dilatation of the stricture was not per-
formed in all cases. The distal end of the stenosis was
marked with a haemostatic clip. The stent delivery system
was advanced through the stricture, and the stent was
deployed under fluoroscopic and endoscopic control. Stent
placement was performed by one of several endoscopists
(7 in total), during regular time, all with experience in
pancreatobiliary endoscopy. Each endoscopist had, at
least, a mean number of attempts per month of 1.5. Three
different types of stent were used: a) from October 2001
to November 2005, the Wallstent enteral stent (Boston
Scientific, Natick, Massachusetts, USA), 20 or 22 mm in
diameter and 6 or 9 cm in length was used by a through-
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the-scope method; b) between October 2002 and Novem-
ber 2005, the Ultraflex Precision (Boston Scientific, Nat-
ick, Massachusetts, USA), 25 mm in diameter (mid-body)
and 6, 9 or 12 cm in length was used for several cases of
malignant obstruction located in the rectum or distal sig-
moid colon; and c) from November 2005 to the end of
this study, the WallFlex colonic stent (Boston Scientific,
Natick, Massachusetts, USA), 22 or 25 mm in diameter
(mid-body) and 6, 9 or 12 cm in length was used in all
cases. The stent diameter and length were selected at the
discretion of the endoscopist. 
Twenty-four hours after stent deployment, all patients
underwent a plain abdominal X-ray to verify stent expan-
sion and correct position and to assess relief of obstruction.
After stent insertion, all patients were placed on a low-
residue diet with laxatives to prevent stool impaction of the
stent.
End points and definitions
The primary endpoint was long-term clinical efficacy,
defined as sustained relief of obstructive symptoms without
reintervention. Secondary endpoints included technical suc-
cess, immediate clinical success, stent patency, complica-
tions, reinterventions, survival, prognostic factors associated
with stent patency and long-term clinical efficacy and risk
factors for complications. Technical success was defined
as accurate stent deployment across the stricture, with paten-
cy visualised both fluoroscopically and endoscopically.
Immediate clinical success was defined as colonic decom-
pression and relief of obstructive symptoms within 24 hours
after stent placement (1,6). Stent patency was defined as
the period between stent placement and recurrence of
obstructive symptoms caused by stent dysfunction due to
malignant stent obstruction (tumour overgrowth or
ingrowth) or migration. Complications were defined as any
adverse event related to stent placement. Complications
were also divided into early (within 7 days) and late. Stent
migration was diagnosed if the stent moved from its initial
position and was unable to cover the entire stenosis, leading
to recurrence of obstructive symptoms. Reintervention was
defined as any procedure performed after the initial stent
placement, including endoscopic resolution of stool
impaction, subsequent colonic stent insertion due to malig-
nant stent restenosis or migration, balloon dilatation, stent
removal, argon plasma coagulation or surgery.
Follow-up 
Follow-up data were obtained by reviewing patients’
electronic and manual charts and clinical notes from regular
clinic visits and by performing telephone interviews with
the treating physician or family at the time of manuscript
preparation. Patients were followed until death in all cases.
In the case of recurrent obstructive symptoms during fol-
low-up, patients contacted their treating physician in the
institution for clinical evaluation. During clinical evaluation,
repeated colonoscopy was conducted for suspected stent
dysfunction. Reinterventions were performed when neces-
sary, considering the clinical situation and patient prefer-
ence. Elective colostomy was performed after failure of
endoscopic therapy. 
Statistical analysis
All study outcomes were evaluated on an intention-to-
treat basis. The cumulative time until complications, stent
patency and patient survival were estimated by the Kaplan-
Meier product limit method. For the calculation of the stent
patency period, death before stent dysfunction was consid-
ered a censored observation. The 95% CI for long-term clin-
ical efficacy was calculated with the Clopper-Pearson (exact)
method. Potential risk factors for complications and prog-
nostic factors associated with long-term clinical efficacy
were assessed by univariate analysis followed by a multiple
logistic regression. Univariate analysis was conducted using
the qui-square test for categorical variables and Student’s t
test for continuous variables. To determine independent
prognostic factors potentially associated with stent patency,
multivariate Cox proportional hazard models were used.
Age, sex, stent diameter (22 mm or less or 25 mm), type of
malignancy (intrinsic or extrinsic), location of obstruction
(left colon, right colon, anastomosis) and palliative
chemotherapy were the variables included in the univariate
and multivariate analysis. All reported p values were for a
2-tailed test, and a p < 0.05 was considered statistically sig-
nificant. All statistical analyses were performed using the
software package SPSS (Statistical Package for the Social
Sciences) 18 (IBM Corporation, New York, USA).
RESULTS
In total, 89 patients (54 males and 35 females) with a mean
age of 74.0 years (range: 39-97 years) were enrolled in the
study. The patients’ baseline data are shown in Table I. 
Technical and immediate clinical success
Placement of a colorectal SEMS was attempted in 89
patients. Successful insertion was achieved in 85 of 89
patients (95.5%). There were no differences in technical suc-
cess rates for stents placed in the right side of colon compared
with the left side of the colon (93.8 vs. 95.9%; p = 0.71 by
univariate analysis). In 4 patients, technical failure during
stent placement was caused by the inability to pass the stric-
ture with a guidewire. All 4 patients underwent successful
emergent surgery with a colostomy. Immediate clinical suc-
cess was achieved in 81 of 89 attempts (91.0%) and in 81 of
85 successfully inserted stents (95.3%). Of the 85 patients
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with technical success, only in 81 patients improved their
obstructive symptomatology because the remaining 4 patients
developed stent-related perforations, as discussed later. One
patient with advanced disease died several hours after the
onset of the complication. The other 3 patients underwent
successful emergency surgery and required no further inter-
vention until death. 
Sustained relief of obstruction 
Relief of obstruction without intervention was main-
tained from stent insertion until death in 68 of 89 patients
(76.4%, 95% CI 66.2-84.8%) (Fig. 1 and Table II) and in
68 of the 81 patients (83.9%) in whom insertion had imme-
diate clinical success. The long-term clinical efficacy rates
by location were as follows: 14 of 16 patients (87.5%) with
stents placed in the right side of the colon and 54 of 73
patients (74.0%) with stents placed in the left side of the
colon (p = 0.25). During follow-up 6/89 patients (6.7%)
were readmitted for suspected reobstruction that was proven
to be attributed to disease progression and not to SEMS
dysfunction as these patients were submitted to
colonoscopy. Univariate (Table III) and multivariate analy-
sis (logistic model) showed that age, sex, stent diameter,
type of malignancy, location of the stricture and palliative
chemotherapy were not significantly associated with long-
term clinical efficacy.
Complications, reinterventions and risk factors 
for complications
In total, 20 of 89 patients (22.5%) experienced compli-
cations after the procedure (Table IV). Early complications,
namely perforations, were seen in 4 of 89 patients (5.1%).
Perforations occurred after stent placement after a mean
interval of 1 day (range, 1-2). One patient died as a conse-
Table I. Baseline patient data
Characteristic
Gender
Male, n (%) 54 (60.7)
Female, n (%) 35 (39.3)
Age (years), mean ± SD (range) 74.0 ± 10.6 (39-97)
Site of obstruction
Rectum, n (%) 18 (20.2)
Sigmoid colon, n (%) 49 (55.1)
Descending colon, n (%) 4 (4.5)
Splenic flexure, n (%) 2 (2.2)
Transverse colon, n (%) 12 (13.5)
Hepatic flexure, n (%) 4 (4.5)
Stricture location
Right side of the colon, n (%) 16 (18.0)
Left side of the colon, n (%) 73 (82.0)
Aetiology
Colorectal, n (%) 85 (95.5)
Extrinsic compression, n (%) 4 (5.1)
Type of stent
Wallstent, n (%) 39 (43.8)
Ultraflex, n (%) 10 (11.2)
WallFlex, n (%) 40 (44.9)
Stent diameter, mm
″ 22, n (%) 39 (43.8)
≥ 25, n (%) 50 (56.2)
Chemotherapy
Yes, n (%) 24 (27.0)
No, n (%) 65 (73.0)
SD: standard deviation.
Fig. 1. Long-term sustained relief of obstruction without reintervention
throughout the patients’ lives after palliative stent placement (solid line)
and 95% CI (dashed line).
Table II. Outcomes after attempted stent placement for
symptomatic malignant colorectal obstruction in 89 patients 
Outcomes
Technical success, n/total (%)                                 84/89 (95.5)
Immediate clinical success, n/total (%)                    81/89 (91.0)
Long-term sustained relief of obstruction 
without intervention, n/total (%)                          68/89 (76.4)
Long-term sustained relief of obstruction 
after subsequent stent placement because 
of stent dysfunction, n/total (%)                           76/89 (85.4)
Patients needing a colostomy for long-term 
relief of the obstructive symptoms, n/total (%)      12/89 (13.5)
Complications, n/total (%)                                      20/89 (22.5)
Mortality procedure related, n/total (%)                    1/89 (1.1)
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quence of the perforation (stent-related mortality: 1.1%),
and the remaining 3 patients underwent successful emergent
surgery. Following surgery, these patients were free from
obstruction until death. Late complications were observed
in 16 of 89 patients (17.9%), including stent obstruction
(n = 8; 9.0%), migration (n = 5; 5.6%) and haemorrhage
(n = 3; 3.4%). Malignant restenosis was experienced at 58,
68, 75, 92, 101, 111, 121 and 366 days after stent placement
(median time to reobstruction: 96.5 days). One patient with
reobstruction required successful surgery with a colostomy,
and in the remaining 7 patients, stent obstruction was suc-
cessfully managed by subsequent stent insertion with res-
olution of obstructive symptoms. All of these 7 patients
maintained relief of obstructive symptoms until death.
Bleeding from the tumour through the mesh of the stent
was seen in 3 patients. The haemorrhage was successfully
managed by endoscopic intervention using argon plasma
coagulation without the need for transfusion. Migration
was encountered in 5 patients at 14, 21, 23, 114 and 196
days after stent placement (median time to migration:
23 days). One patient with migration was successfully man-
aged by subsequent insertion of a stent with a larger diam-
eter, and the remaining 4 patients were submitted to surgery
with colostomy. All 5 patients were free from obstructive
symptoms until death. Kaplan-Meier analysis estimated
that the mean time to complications after stent insertion
was 288.2 days (range, 1-366) (95% CI 237.4-237.4)
(Fig. 2). In total, 12 of the initial 89 patients (13.5%) needed
a colostomy for long-term relief of the obstructive symp-
toms. Univariate analysis and the multivariate logistic mod-
el revealed no significant risk factors associated with com-
plications; however, a logistic model for individual
complications (migration, obstruction and perforation)
showed a non-significant trend towards the use of palliative
chemotherapy as a risk factor for migration (OR=11.89;
95% CI=0.90-157.47; p = 0.06) (Table V).
Survival, stent patency and prognostic factors 
for stent patency
The median and mean survival periods were 87.0 (range,
4-565) (95% CI 43.9-130.1) and 116.0 days (95% CI 92.5-
139.5) (Fig. 3), respectively. The survival rates were 21.3%
(95% CI 12.8-29.9%) at 6 months and 4.5% (95% CI 0.2-
8.8%) at 1 year. Loss of stent patency occurred in 13 of 89
patients (14.6%) as a result of stent dysfunction (stent
obstruction in 8 patients and migration in 5 patients). The
mean stent patency was 322.7 days (range, 14-366) (95% CI
Table III. Univariate analysis of prognostic factors associated
with long-term clinical efficacy
                                     Clinical         Success, n (%)            
                                        Yes                    No                    p
Sex                                                                                   0.71
Male                           42 (77.8)           12 (22.2)                
Female                        26 (74.3)            9 (25.7)                 
Age (Mean ± SD)       73.8 ± 10.90       74.9 ± 9.8            0.67
Stricture location                                                              0.25
Right colon                 14 (87.5)            2 (12.5)
Left colon                   54 (74.0)           19 (26.0)
Stent diameter                                                                 0.16
22 mm                       27 (69.2)           12 (30.8)
25 mm                       41 (82.0)            9 (17.0)
Aetiology                                                                          0.20
Colorectal                   66 (77.6)           19 (22.4)
Extrinsic                       2 (50.0)             2 (50.0)
Chemotherapy                                                                  0.45
Yes                             17 (70.8)            7 (29.2)
No                              51 (78.5)           14 (21.5)
SD: standard deviation.
Table IV. Complications and management
Complications n (%) Management (n)
Perforation 4 (4.5) Surgery (4)
Stent dysfunction 13 (14.6)
Obstruction 8 (9.0) Surgery (1), subsequent 
stent insertion (7)
Migration 5 (5.6) Surgery (4), subsequent 
stent insertion (1)
Haemorrhage 3 (3.4) Argon plasma coagulation (3)
Total 20 (22.5) -
Fig. 2. Kaplan-Meier estimated time until the onset of complications.
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273.4-372.0) (Fig. 4). Kaplan-Meier method did not estimate
median stent patency because more than 50% of observations
were censored early in the analysis. Multivariate Cox regres-
sion analysis showed that age (HR 1.07, 95% CI 0.97-1.18;
p = 0.15), sex-female (HR 3.95, 95% CI 0.80-19.56, p =
0.92), stent diameter-22mm (HR 1.14, 95% CI 0.30-4.25;
p = 0.85), type of malignancy-colorectal (HR 0.22, 95% CI
00.4-1.27, p = 0.09), location of the stricture-right/left (HR
0.15, 95% CI 0.01-1.54; p = 0.11), and palliative chemother-
apy (HR 5.51, 95% CI 0.86-35.29; p = 0.07) were not sig-
nificantly associated with stent patency.
DISCUSSION
According to our findings in a retrospective, single-arm,
multicentre study, the use of a SEMS for definitive pallia-
tion of malignant colorectal obstruction was associated with
the sustained, lifelong relief of obstructive symptoms with-
out the need for reintervention in 76.4% of patients. The
complication rate was 22.5%, and perforation was seen in
4.5% of the patients. The stent-related mortality rate was
1.1%. In total, 12 of the initial 89 patients (13.5%) needed
a colostomy for long-term relief of the obstructive symp-
toms. The multivariate logistic model revealed a non-sig-
nificant trend by which the use of palliative chemotherapy
was a risk factor for migration (p = 0.06).
SEMS were developed to provide rapid and effective
relief of colonic obstruction and are an effective alternative
to surgery. Several studies have suggested that there are
advantages of stents over emergency surgery, either as a
bridge to elective 1-stage surgery or as a palliative treatment
(1,9,16). Three randomised trials have compared colostomy
to endoscopic stenting for palliation of malignant colorectal
obstruction (5,17,18). One study enrolling 30 patients
showed that placement of a metal stent yielded similar out-
Table V. Results of a multivariate logistic model to evaluate risk factors for complications
                                                 Migration                                                Obstruction                                                Perforation           
                                   OR          95% CI             p                      OR            95% CI              p                     OR             95% CI            p
Age                            1.05        0.92-1.19         0.47                  1.12         0.99-1.26         0.08                  0.97          0.87-1.08        0.55
Sex-female                  3.14       0.30-32.54        0.34                  3.02        0.51-17.91        0.22                  0.43          0.04-4.56        0.48
Stent diameter 
(22 mm)                    1.19       0.14-10.45        0.89                  2.06        0.35-12.11        0.42                  0.49          0.05-5.13        0.55
Location
Right colon               0.00             NC              0.99                  0.41         0.04-4.56         0.47                  0.00               NC             0.99
Aetiology 
Colorectal                0.25        0.01-4.53         0.35                  0.35         0.02-5.13         0.45                  0.00               NC             0.99
CT                             11.89     0.90-156.47       0.06                  2.48        0.50-13.08        0.35                  0.00               NC             0.99
CT: Chemotherapy; NC: not computed.
Fig. 3. Kaplan-Meier curves of estimated survival. Fig. 4. Estimated stent patency based on Kaplan-Meier analysis.
comes when compared with surgery, but the stent was asso-
ciated with a better quality of life for the patient and with
fewer costs (17). In another study enrolling 22 patients,
endoscopic stenting was significantly more effective in
terms of operative time, restoration of bowel function,
restoration of oral food intake and reduction in median hos-
pitalisation (18). However, a recent trial was terminated
prematurely because of the high number of perforations (n
= 6) in the nonsurgical arm, which resulted in 3 deaths
among 10 patients (5). The authors concluded that the high
perforation rate could be either specifically WallFlex-related
or enteral-stent-related in patients on chemotherapy. In con-
trast, one study conducted in the same year as the previously
cited randomised trial and using the WallFlex stent was
associated with a perforation rate below 5% (19), which is
in line with previous studies using other stents (11,14,20). 
The results of prospective trials and of recent retrospec-
tive studies further demonstrated the effectiveness of SEMS
in the palliative management of malignant colorectal
obstruction (6,7,12-14,21). In this study, sustained relief of
obstructive symptoms without reintervention was the pri-
mary outcome. A total of 76.4% of the patients were free
from obstruction until death. These results were measured
on an intention-to-treat basis; per-protocol analysis yielded
an improved long-term clinical efficacy of 83.9%. Further-
more, among the 14.6% of patients in whom reobstruction
was caused by stent dysfunction, the placement of another
stent prolonged the benefit of the majority (8/13, 61.5%)
of endoscopically treated patients. In this study, no signif-
icant prognostic factors for long-term clinical efficacy have
emerged. One study reported that shorter stents (< 10 cm)
and distal colorectal obstruction are associated with better
stent outcomes (12). One additional important observation
in our study is the similar long-term clinical efficacy
between stents placed in the left side of the colon and SEMS
placed in the right side of the colon (87.5 vs. 74.0% respec-
tively). In this study, the number of included patients with
obstruction in the proximal colon was relatively high (n =
16), and the effectiveness of proximal colon stenting was
previously reported in a multicentre retrospective study of
21 patients (22). Finally, in the present study, there was a
substantial difference between the estimated mean survival
(116.0 days) and mean stent patency (322.7 days), suggest-
ing that colorectal stenting is able to keep the majority of
patients free from obstruction until death. 
Few studies have addressed the long-term sustained relief
of colorectal obstruction from stent placement until death,
as the majority of reports have either limited follow-up or
a significant number of patients lost to follow-up. A
prospective multicentre study addressed the long-term clin-
ical efficacy of colorectal stents in 44 patients with malig-
nant colonic obstruction. During the study, 14 patients died
and 12/14 (86%) of the non-survivors were clinical suc-
cesses (7). A large retrospective study conducted over a 9-
year period analysed the outcomes of 168 patients who
underwent SEMS placement for palliation. At 6 months,
the estimated clinical success rate was 77.2%, and relief of
obstruction was maintained from stent implantation until
death in 108/122 of the patients (88.5%) (6). Taken together,
the results of these studies and of the current study provide
evidence that the long-term clinical efficacy of SEMS can
be maintained until death in the great majority of patients.
Furthermore, the benefits of stenting can be of high value
in obstructed patients with a relatively short expected sur-
vival, as surgery in these patients may even be considered
unethical, having a profoundly negative impact on quality
of life (2,13).
In this study, technical success was achieved in 95.5% of
the patients, a rate consistent with the largest published pooled
analysis, which reported a technical success rate of 93.24%
(range 64 to 100%) (11). In the current study, there were no
differences in the technical success rates for stents placed in
the right versus the left side of the colon (93.8 vs. 95.9%),
suggesting that the through-the-scope technique makes all
tumour locations accessible from a technical perspective. In
the present study, immediate clinical success was observed
in 91.0% of the patients who were able to avoid surgery.
These results were in keeping with the results of the previ-
ously cited pooled analysis, in which clinical success was
achieved in 88.56% of the patients (range, 55-100%) (11). 
When SEMS placement is considered for definitive pal-
liation of malignant colorectal obstruction, safety is an impor-
tant issue. The most frequent complications are perforations,
stent obstruction, stent migration and bleeding. In this study,
the complication rate was 22.5%, very similar to the results
of other studies with an overall complication rate of 25%
(6,11,14); however, relevant complications (namely perfo-
rations) are not common. In this study, perforation was seen
in 4.5% of patients. This result is in line with the literature,
in which perforation occurred in 0 to 9% of cases, with an
average of 5% (6,7,11,13,14,21). Proposed risk factors for
perforation include balloon predilatation, concomitant
chemotherapy and bevacizumab-based chemotherapy
(5,6,13,17,18,23). In this study, balloon dilatation was not
done and chemotherapy was not associated with perforation
in multivariate analysis, as previously reported by others (1).
However, the addition of bevacizumab to cancer therapy sig-
nificantly increases the risk of colorectal perforation, and this
risk is further increased in patients submitted to SEMS place-
ment for palliative colorectal obstruction (5,13,23). In this
study, the stent migration rate was 5.1%, which is low when
compared with older studies reporting values between 9 and
16% (11,14). In fact, the problem of stent migration seems
to be declining as a result of increasing use of stents specif-
ically designed for colons with larger diameters. In the current
study, 56.2% of the patients were submitted to stents with
diameters of 25 mm, and this approach may explain our low
migration rate. In this study, the multivariate logistic model
showed a non-significant trend by which the use of palliative
chemotherapy constituted a risk factor for migration. This
result suggests that concomitant chemotherapy may enhance
tumour reduction, leading to migration in the long-term. One
of the most common complications of colorectal stenting is
stent reobstruction. In this study, the stent occlusion rate was
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9.0%, which is in line with recent literature reporting an occlu-
sion rate between 9 and 17% (1,4,6,12). Recently, the inser-
tion of an additional stent has become standard in the treat-
ment of stent occlusion. In our study, among the 9.0% of
patients in whom reobstruction was seen, subsequent stent
placement further increase the benefit of stenting in the major-
ity (7/8, 87.5%) of patients treated with SEMS. 
Several limitations of our study should be taken into
account. First, this was a study with a retrospective design
limiting the number of included patients because some of
the identified consecutive patients had incomplete data and
were excluded from the analysis. Our data may therefore
have been subject to selection bias. Another potential weak-
ness is the single-arm design, with no comparison to other
available treatments, especially to palliative surgery. We
suggest that further prospective randomised studies are
needed. Surgery must be compared to endoscopic stenting
in a large population in order to have adequate power to
detect minor differences in outcome. In these proposed
studies, long-term complications and quality of life should
be carefully evaluated. The endoscopists involved in the
procedures were very experienced, and we cannot exclude
a poorer outcome in community or district general hospitals.
However, in a large cohort of patients Garcia-Cano et al.
reported similar results between referral centres and smaller
hospital suggesting that colonic stent placement could be
feasibly performed in general endoscopic practice (20). The
strengths of our study are the design, which allowed us to
follow a cohort of patients from stent insertion until death
in all cases, and the relatively large sample size.
In conclusion, our data suggest that the placement of a
SEMS for definitive palliation of incurable malignant col-
orectal obstruction is a useful tool that can provide sustained
relief of obstruction without reintervention in approximately
75% of patients. The procedure provides rapid and effective
relief of obstruction and is associated with acceptable mor-
bidity, acceptable need for reintervention and minimal mor-
tality.
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